Imlifidase for Goodpasture Syndrome
(GOOD-IDES-02 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to evaluate the effectiveness of a new treatment, imlifidase, for individuals with severe anti-GBM disease, a rare condition affecting the kidneys and lungs. Participants will receive either imlifidase (an enzyme-based therapy) combined with standard treatments or only the standard treatments to compare outcomes. The trial seeks individuals with anti-GBM antibodies (a type of protein in the blood), blood in their urine, and very low kidney function. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants an opportunity to contribute to potentially groundbreaking treatment advancements.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, if you have received IVIg (a type of immune therapy) within 4 weeks before joining, you cannot participate. It's best to discuss your current medications with the trial team.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that imlifidase is generally safe for patients. In earlier studies, two-thirds of patients with anti-GBM disease who received imlifidase stopped using dialysis within six months. This outcome indicates that the treatment is effective and does not cause serious side effects. Imlifidase has also received approval for severe anti-GBM disease, supporting its safety for this condition. It works by quickly lowering harmful antibodies, which helps protect the kidneys. While all treatments carry some risks, current data suggests that imlifidase is a promising and manageable option for those with severe anti-GBM disease.12345
Why do researchers think this study treatment might be promising?
Imlifidase is unique because it offers a new approach to treating Goodpasture Syndrome. While standard treatments typically involve a combination of procedures and medications like plasma exchange (PLEX), cyclophosphamide (CYC), and glucocorticoids, imlifidase works by breaking down antibodies that attack the body's own tissues. This mechanism can rapidly reduce harmful antibodies, potentially offering faster relief compared to traditional methods. Researchers are excited about imlifidase because it could provide a quicker, more targeted response, improving outcomes for patients with this challenging condition.
What evidence suggests that imlifidase might be an effective treatment for Goodpasture Syndrome?
Research has shown that current treatments for Goodpasture syndrome, such as plasma exchange (PLEX), cyclophosphamide (CYC), and steroids, often fail to preserve kidney function. Less than 30% of patients retain kidney function after 6 to 12 months. In this trial, participants will receive either the standard-of-care (SoC) treatment alone or in combination with Imlifidase. Researchers are testing Imlifidase because it breaks down the harmful antibodies that attack the kidneys in this disease. Early results suggest that Imlifidase might help maintain kidney function better than existing treatments alone. This potential makes it an important option for those dealing with this condition.16789
Who Is on the Research Team?
Clinical Operations
Principal Investigator
Hansa Biopharma AB
Are You a Good Fit for This Trial?
This trial is for adults over 18 with severe anti-GBM disease, indicated by specific kidney function tests and presence of certain antibodies. They must have blood in their urine and not have been treated with standard care or immune globulins recently. Pregnant or breastfeeding individuals, those with conditions posing extra risks, or anuria (no urine output) in the last day are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either imlifidase and SoC or SoC alone. Imlifidase is administered IV as one dose of 0.50 mg/kg over 30 minutes.
Follow-up
Participants are monitored for safety, renal function, anti-GBM antibody levels, and health-related quality of life.
What Are the Treatments Tested in This Trial?
Interventions
- Imlifidase
Trial Overview
The study compares a new treatment approach using Imlifidase alongside standard therapies like plasma exchange, cyclophosphamide, and glucocorticoids against the standard treatments alone. It's designed to see if adding Imlifidase improves kidney function in patients with anti-GBM disease over two years.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Active Control
* Imlifidase is administered IV as one dose of 0.50 mg/kg over 30 minutes. * SoC consists of a standardized combination of PLEX, CYC, and glucocorticoids.
SoC consists of a standardized combination of PLEX, CYC, and glucocorticoids.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Hansa Biopharma AB
Lead Sponsor
Citations
Anti–Glomerular Basement Membrane Disease
Kidney outcomes in anti–glomerular basement membrane disease remain poor despite significant improvement in patient survival in the last 2 to 3 decades.
2.
hansabiopharma.com
hansabiopharma.com/media/press-releases/2024/hansa-biopharma-completes-enrolment-in-global-pivotal-phase-3-trial-of-imlifidase-in-anti-glomerular-basement-membrane-disease/Hansa Biopharma Completes Enrolment in Global Pivotal ...
The majority of patients with anti-GBM today lose kidney function and two-thirds experience kidney failure requiring long-term dialysis. We look ...
NCT05679401 | A Study With Imlifidase in Anti-GBM Disease
An open-label, controlled, randomised, multi-centre Phase 3 trial evaluating renal function in patients with severe anti-GBM disease comparing imlifidase and ...
Using imlifidase to elucidate the characteristics and ...
The prognosis of anti-GBM nephritis with current standard therapy is disappointing, with less than 30% renal survival after 6–12 months, hence, elucidating the ...
5.
ucla.clinicaltrials.researcherprofiles.org
ucla.clinicaltrials.researcherprofiles.org/trial/NCT05679401Imlifidase in Anti-GBM Disease - Clinical Trials at UCLA
An open-label, controlled, randomised, multi-centre Phase 3 trial evaluating renal function in patients with severe anti-GBM disease comparing imlifidase and ...
6.
hansabiopharma.com
hansabiopharma.com/media/press-releases/2020/hansa-biopharm-announces-positive-high-level-data-from-investigator-initiated-phase-2-trial-with-imlifidase-to-treat-anti-gbm-disease/Hansa Biopharm announces positive high-level data from ...
Study concludes that imlifidase leads to rapid clearance of anti-GBM antibodies, with two-thirds of patients achieving dialysis independence six months after ...
Goodpasture Syndrome - StatPearls - NCBI Bookshelf - NIH
Another promising medication is imlifidase, an IgG protease approved for severe anti-GBM disease. Studies show a reduction in antibody ...
Efficacy and Safety of Rituximab in Antiglomerular ...
Rituximab has been postulated as a potential treatment for anti-GBM disease; however, data on efficacy and safety are lacking. Methods. We performed a review ...
Hansa starts dosing in Phase III trial in anti-GBM disease
In March 2022, Hansa announced that two-thirds of patients achieved dialysis independence after the treatment compared to 18% of patients in a ...
Other People Viewed
By Subject
By Trial
Related Searches
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.